Advertisement

Current Rheumatology Reports

, Volume 8, Issue 4, pp 317–322 | Cite as

Neuro-behçet’s syndrome: Differential diagnosis and management

  • Erdal DiriEmail author
  • Louis R. Espinoza
Article

Abstract

Behçet’s syndrome (BS) is a multisystem disease of unknown etiology, characterized by chronic relapsing cardinal symptoms of orogenital ulcers, uveitis, and different skin lesions. Its major pathologic feature is vasculitis. Neuro-Behçet’s syndrome (NBS) is defined as a constellation of neurologic manifestations with characteristic neuropathologic findings, usually confirmed by ancillary investigations, in patients who meet the diagnostic criteria for BS. Neurologic manifestations of the syndrome are more common in male patients and have been reported to occur in anywhere from 5% to 50% of BS patients, depending on their geographical region. NBS primarily affects the central nervous system and includes parenchymal and nonparenchymal involvement. Peripheral neuropathy and myopathy are rare. Immunosuppression is widely used for treatment.

Keywords

Uveitis Neurologic Manifestation Central Nervous System Manifestation Central Nervous System Vasculitis Single Photon Emission Compute Tomog 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Barnes CG: Treatment of Behcet’s syndrome. Rheumatology 2006, 45:245–247. Article reviews general aspects and therapy of Behçet’s syndrome well.PubMedCrossRefGoogle Scholar
  2. 2.
    Uber rezidivierende aphthose durch ein virus verursachte Behçet H. geschwure am mund, am auge und an den genitalien [in German]. Dermatol Wochenschr 1937, 105:1152–1157.Google Scholar
  3. 3.
    Tunc R, Keyman E, Melikoglu M, et al.: Target organ associations in Turkish patients with Behcet’s disease: a cross sectional study by exploratory factor analysis. J Rheumatol 2002, 29:2393–2396.PubMedGoogle Scholar
  4. 4.
    Yazici H: Behcet’s syndrome: Where do we stand? Am J Med 2002, 112:75–76. An editorial from an expert in the area of Behçet’s syndrome.PubMedCrossRefGoogle Scholar
  5. 5.
    Diri E, Mat C, Hamuryudan V, et al.: Papulopustular skin lesions are seen more frequently in patients with Behcet’s syndrome who have arthritis: a controlled and masked study. Ann Rheum Dis 2001, 60:1074–1076.PubMedCrossRefGoogle Scholar
  6. 6.
    Sakane T, Takeno M, Suzuki N, Inaba G: Behcet’s disease. N Engl J Med 1999, 341:1284–1291.PubMedCrossRefGoogle Scholar
  7. 7.
    Kaklamani VG, Vaiopoulos G, Kaklamanis PG: Behcet’s disease. Semin Arthritis Rheum 1998, 27:197–217.PubMedCrossRefGoogle Scholar
  8. 8.
    Poon W, Verity DH, Larkin GL, et al.: Behcet’s disease in patients of west African and Afro-Caribbean origin. Br J Ophthalmol 2003, 87:876–878.PubMedCrossRefGoogle Scholar
  9. 9.
    Yurdakul S, Gunaydin I, Tuzun Y, et al.: The prevalence of Behcet’s syndrome in a rural area in northern Turkey. J Rheumatol 1988, 15:820–822.PubMedGoogle Scholar
  10. 10.
    Nakae K, Masaki F, Hashimoto T, et al.: Recent epidemiological features of Behçet’s disease in Japan. In: Behçet’s disease. Edited by Wechsler B, Godeau P. Amsterdam: Excerpta Medica; 1993:145–151.Google Scholar
  11. 11.
    Yazici H, Tuzun Y, Pararli H, et al.: Influence of age of onset and patient’s sex on the prevalence and severity of manifestations of Behcet’s syndrome. Ann Rheum Dis 1984, 43:783–789.PubMedGoogle Scholar
  12. 12.
    Fietta P: Behcet’s disease: familial clustering and immunogenetics. Clin Exp Rheumatol 2005, 23(Suppl 38):S96-S105. This very comprehensive and detailed article reviews the immunogenetics of Behçet’s syndrome.PubMedGoogle Scholar
  13. 13.
    Yazici H, Chamberlain MA, Tuzun Y, et al.: A comparative study of the pathergy reaction among Turkish and British patients with Behcet’s disease. Ann Rheum Dis 1984, 43:74–75.PubMedCrossRefGoogle Scholar
  14. 14.
    Bonfioli AA, Orefice F: Behcet’s disease. Semin Ophthalmol 2005, 20:199–206.PubMedCrossRefGoogle Scholar
  15. 15.
    Atzeni F, Sarzi-Puttini P, Doria A, et al.: Behcet’s disease and cardiovascular involvement. Lupus 2005, 14:723–726. Article contains an in-depth review of the cardiovascular involvement in Behçet’s syndrome, as well as the authors’ own related clinical experience.PubMedCrossRefGoogle Scholar
  16. 16.
    Melikoglu M, Altiparmak MR, Fresko I, et al.: A reappraisal of amyloidosis in Behcet’s syndrome. Rheumatology 2001, 40:212–215.PubMedCrossRefGoogle Scholar
  17. 17.
    International Study Group for Behcet’s Disease: Criteria for diagnosis of Behcet’s disease. Lancet 1990, 335:1078-1080.Google Scholar
  18. 18.
    Borhani Haghighi A, Pourmand R, Nikseresht AR: Neuro-Behcet disease: a review. Neurologist 2005, 11:80–89. The authors provide a comprehensive overview of neuro-Behçet’s syndrome.CrossRefGoogle Scholar
  19. 19.
    Chin RL, Latov N: Central nervous system manifestations of rheumatologic diseases. Curr Opin Rheumatol 2005, 17:91–99. This paper has a good discussion of the differential diagnosis of rheumatic disorders causing central nervous system manifestations.PubMedCrossRefGoogle Scholar
  20. 20.
    Serdaroglu P, Yazici H, Ozdemir C, et al.: Neurologic involvement in Behcet’s syndrome: a prospective study. Arch Neurol 1989, 46:265–269.PubMedGoogle Scholar
  21. 21.
    Akman-Demir G, Serdaroglu P, Tasci B: Clinical patterns of neurological involvement in Behcet’s disease: evaluation of 200 patients. The Neuro-Behcet Study Group. Brain 1999, 122:2171–2182. This excellent report describes in detail the neurological manifestations in a large population of patients with Behçet’s. Prognostic factors are also discussed.PubMedCrossRefGoogle Scholar
  22. 22.
    Lakhanpal S, Tani K, Lie JT, et al.: Pathologic features of Behcet’s syndrome: a review of Japanese autopsy registry data. Hum Pathol 1985, 16:790–795.PubMedCrossRefGoogle Scholar
  23. 23.
    Kone-Paut I, Gorchakoff-Molinas A, Weschler B, Touitou I: Paediatric Behcet’s disease in France [letter]. Ann Rheum Dis 2002, 61:655–656.PubMedCrossRefGoogle Scholar
  24. 24.
    Siva A, Kantarci OH, Saip S, et al.: Behcet’s disease: diagnostic and prognostic aspects of neurological involvement. J Neurol 2001, 248:95–103. This is a well-designed study describing the frequencies of the different neurologic manifestations of Behçet’s syndrome.PubMedCrossRefGoogle Scholar
  25. 25.
    Mirsattari SM, McGinn GJ, Halliday WC: Neuro-Behcet disease with predominant involvement of the brainstem. Neurology 2004, 63:382–384.PubMedGoogle Scholar
  26. 26.
    Kidd D, Steuer A, Denman AM, Rudge P: Neurological complications in Behcet’s syndrome. Brain 1999, 122:2183–2194.PubMedCrossRefGoogle Scholar
  27. 27.
    Davis LE, Hodgin UG, Kornfeld M: Recurrent meningoencephalitis with recovery from Behcet’s disease. West J Med 1986, 145:238–239.PubMedGoogle Scholar
  28. 28.
    Aykutlu E, Baykan B, Akman-Demir G, et al.: Headache in Behcet’s disease. Cephalalgia 2006, 26:180–186.PubMedCrossRefGoogle Scholar
  29. 29.
    Wechsler B, Vidailhet M, Piette JC, et al.: Cerebral venous thrombosis in Behcet’s disease: clinical study and long-term follow-up of 25 cases. Neurology 1992, 42:614–618.PubMedGoogle Scholar
  30. 30.
    Ho CL, Deruytter MJ: Manifestations of Neuro-Behcet’s disease: report of two cases and review of the literature. Clin Neurol Neurosurg 2005, 107:310–314.PubMedCrossRefGoogle Scholar
  31. 31.
    Zelenski JD, Capraro JA, Holden D, Calabrese LH: Central nervous system vasculitis in Behcet’s syndrome: angiographic improvement after therapy with cytotoxic agents. Arthritis Rheum 1989, 32:217–220.PubMedCrossRefGoogle Scholar
  32. 32.
    Dong ZH, Fu WG, Guo DQ, et al.: Endovascular repair for a huge vertebral artery pseudoaneurysm caused by Behcet’s disease. Chin Med J 2006, 119:435–437.PubMedGoogle Scholar
  33. 33.
    Yazici H, Yurdakul S, Hamuryudan V, Fresko I: Behçet’s syndrome. In Rheumatology. Edited by Hochberg MC, Silman AJ, Smolen JS, et al.: Madrid, Spain: Mosby; 2003:1665–1669.Google Scholar
  34. 34.
    Reske D, Petereit HF, Heiss WD: Difficulties in the differentiation of chronic inflammatory diseases of the central nervous system-value of cerebrospinal fluid analysis and immunological abnormalities in the diagnosis. Acta Neurol Scand 2005, 112:207–213. Article describes a good study of the value of cerebrospinal fluid analysis in the differential diagnosis of immunologic conditions affecting the central nervous system.PubMedCrossRefGoogle Scholar
  35. 35.
    Sharief MB, Hentges R, Thomas E: Significance of CSF immunoglobulins in monitoring neurologic disease activity in Behcet’s disease. Neurology 1991, 41:1398–1401.PubMedGoogle Scholar
  36. 36.
    Saruhan-Direskeneli G, Yentur SP, Akman-Demir G, et al.:Cytokines and chemokines in neuro-Behcet’s disease compared to multiple sclerosis and other neurological diseases. J Neuroimmunol 2003, 145:127–134.PubMedCrossRefGoogle Scholar
  37. 37.
    Akman-Demir G, Bahar S, Coban O, et al.: Cranial MRI in Behcet’s disease: 134 examinations of 98 patients. Neuroradiology 2003, 45:851–859. Article reports in detail the cranial MRI findings of neuro-Behçet’s syndrome.PubMedCrossRefGoogle Scholar
  38. 38.
    Erdem H, Dinc A, Pay S, et al.: A neuro-Behcet’s case complicated with intracranial hypertension successfully treated by a lumboperitoneal shunt. Joint Bone Spine 2006, 73:200–201.PubMedCrossRefGoogle Scholar
  39. 39.
    Motomura S, Tabira T, Kuroiwa Y: A clinical comparative study of multiple sclerosis and neuro-Behcet’s syndrome. J Neurol Neurosurg Psychiatry 1980, 43:210–213.PubMedGoogle Scholar
  40. 40.
    McLean BN, Miller D, Thompson EJ: Oligoclonal banding of IgG in CSF, blood-brain barrier function, and MRI findings in patients with sarcoidosis, systemic lupus erythematosus, and Behcet’s disease involving the nervous system. J Neurol Neurosurg Psychiatry 1995, 58:548–554.PubMedGoogle Scholar
  41. 41.
    Diri E, Espinoza CG, Espinoza LR: Spinal cord granulomatous vasculitis: an unusual clinical presentation of sarcoidosis. J Rheumatol 1999, 26:1408–1410.PubMedGoogle Scholar
  42. 42.
    Siva A, Kantarcy OH, Saip S, et al.: Behcet’s disease: diagnostic and prognostic aspects of neurological involvement. J Neurol 2001, 248:95–103.PubMedCrossRefGoogle Scholar
  43. 43.
    Siva A, Fresko I I: Behcet’s disease. Curr Treat Options Neurol 2000, 2:435–448.PubMedGoogle Scholar
  44. 44.
    O’Duffy JD, Robertson DM, Goldstein NP: Chlorambucil in the treatment of uveitis and meningoencephalitis of Behcet’s disease. Am J Med 1984, 76:75–84.PubMedCrossRefGoogle Scholar
  45. 45.
    Ranselaar CG, Boone RM, Kluin-Nelemans HC: Thalidomide in the treatment of neuro-Behcet’s syndrome. Br J Dermatol 1986, 115:367–370.PubMedCrossRefGoogle Scholar
  46. 46.
    Calguneri M, Ozturk MA, Ertenli I, et al.: Effects of interferon alpha treatment on the clinical course of refractory Behcet’s disease: an open study. Ann Rheum Dis 2003, 62:492–493.PubMedCrossRefGoogle Scholar
  47. 47.
    Sarwar H, McGrath H, Jr, Espinoza LR: Successful treatment of long-standing neuro-Behcet’s disease with infliximab. J Rheumatol 2005, 32:181–183.PubMedGoogle Scholar
  48. 48.
    Ribi C, Sztajzel R, Delavelle J, Chizzolini C: Efficacy of TNF alpha blockade in cyclophosphamide resistant neuro-Behcet disease. J Neurol Neurosurg Psychiatry 2005, 76:1733–1735.PubMedCrossRefGoogle Scholar
  49. 49.
    Wechsler B, Gerber S, Vidailhet M, Dormont D: Neurologic manifestations of Behcet’s disease [in French]. Ann Med Interne 1999, 150:555–561.Google Scholar
  50. 50.
    Hirohata S, Suda H, Hashimoto T: Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Behcet’s disease. J Neurol Sci 1998, 159:181–185.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  1. 1.Rheumatology, Trinity HospitalMinotUSA

Personalised recommendations